Veradermics Announces Topline Results Conference for Phase 2/3 VDPHL01 Oral Minoxidil Trial in Male Pattern Hair Loss

on

Veradermics is hosting an investor conference call to discuss topline results from Part A of its Phase 2/3 '302' trial evaluating VDPHL01, an extended-release oral minoxidil tablet, in males with mild-to-moderate pattern hair loss.1

Preliminary Phase 2 trial data showed an average increase of 47.3 non-vellus hairs/cm² after 4 months at 8.5 mg twice daily, with 90.5% of participants reporting improved hair coverage and no serious adverse events, including cardiac issues.3

VDPHL01 outperformed topical 5% minoxidil (Rogaine) and low-dose immediate-release oral minoxidil in early studies, with 82% achieving moderate to great improvement vs. 20% for comparators in shorter time.4

Enrollment completed in two Phase 3 trials ('302' and '304') for males involving over 1,000 participants; topline results from first male study expected in first half of 2026.2

VDPHL01 uses a gel matrix for steady minoxidil release to promote hair growth while minimizing cardiac risks from peak concentrations.13

Trials ongoing for females; if approved, VDPHL01 could be the first FDA-approved oral non-hormonal treatment for pattern hair loss in both sexes.15

Sources:

1. https://www.biospace.com/press-releases/veradermics-to-hold-conference-call-to-discuss-topline-results-from-phase-2-3-302-study-of-vdphl01-in-males-with-mild-to-moderate-pattern-hair-loss

2. https://www.clinicaltrialsarena.com/news/veradermics-concludes-enrolment-vdphl01-trial/

3. https://www.veradermics.com/about-vdphl01/

4. https://www.hairlosscure2020.com/category/veradermics/

5. https://emrahcinik.com/vdphl01-minoxidil-oral-new-treatment/